胃癌治疗新药前景
本文综述胃癌新型治疗靶点与在研药物,检索PubMed及美国临床肿瘤学会、欧洲肿瘤内科学会、日本肿瘤内科学会会议网站。HER2靶向联合策略、STAT3抑制、DNA损伤修复、Claudin 18.2、PD-1/PD-L1抑制剂及基质金属蛋白酶-9抑制等方向已获初步有希望的结果。
要点
- 曲妥珠单抗靶向HER2对HER2阳性转移性胃癌有效,联合HER2靶向策略正在研究中。
- 围手术期HER2靶向治疗的研究正在进行中。
- 新靶点包括STAT3相关信号通路、DNA损伤修复、Claudin 18.2及肿瘤微环境调节。
核心结论
- 胃癌患者的新型治疗选择正在涌现,涉及新作用机制,基于对肿瘤生物学的不断深入理解和更好的分子分层。
研究设计与样本
- 综述,检索PubMed及美国临床肿瘤学会、欧洲肿瘤内科学会、日本肿瘤内科学会会议网站,评估胃癌新治疗靶点和新兴药物疗法的临床前与临床研究。
主要发现
- 曲妥珠单抗靶向HER2在HER2阳性转移性胃癌中有效。
- 联合HER2靶向策略正在研究中,围手术期HER2靶向研究正在进行中。
- STAT3等癌症干性相关信号通路抑制、DNA损伤修复、Claudin 18.2为新型分子药物靶点。
- PD-1/PD-L1检查点抑制剂激活免疫应答及基质金属蛋白酶-9抑制调节基质,已获首批有希望的治疗结果。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Conventional cytotoxic chemotherapy has been the backbone of advanced gastric cancer treatment for decades and still represents a key element of the therapeutic armamentarium. However, only small increments in survival outcomes have been reached. A better understanding of genetic alterations and molecular signatures of gastric cancer has been reached in the last years. It will serve as a roadmap for better treatment stratification and future drug development. MATERIALS AND METHODS: We reviewed preclinical and clinical studies that assessed novel treatment targets and emerging drug therapies in gastric cancer. We performed research via PubMed, and the congress webpages of the American Society of Clinical Oncology, European Society of Medical Oncology and the Japanese Society of Medical Oncology. RESULTS: HER2-targeting with trastuzumab is effective in HER2-positive metastatic gastric cancer; combined HER2 targeting strategies are being investigated. Studies assessing the role of HER2 targeting in the perioperative setting are ongoing. Novel treatment targets include inhibition of cancer stemness-related signaling pathways like STAT3. DNA damage repair and Claudin 18.2, a tight junction protein with high expression in gastric cancers are also novel molecular drug targets. Modification of the tumor microenvironment, including activation of immune response by PD-1/PD-L1 checkpoint inhibitors and stroma modification by matrix metalloproteinase-9 inhibition, led to first promising treatment results. CONCLUSION: Novel treatment options for gastric cancer patients are emerging. They involve novel mechanisms of action, and are based on our constantly increasing understanding of tumor biology and better molecular stratification of gastric cancer patients.
引用
- Lordick F, Shitara K, Janjigian YY, et al. New agents on the horizon in gastric cancer. Ann Oncol. 2017. PMID: 28184417. doi:10.1093/annonc/mdx051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。